New hope for myelofibrosis patients who stopped responding to standard treatment
NCT ID NCT06887803
Summary
This early-stage study is testing whether adding a new drug called roginolisib to the standard treatment ruxolitinib is safe and tolerable for adults with myelofibrosis, a serious bone marrow cancer. It aims to help patients whose disease has not responded well to ruxolitinib alone, looking to reduce symptoms like spleen enlargement and fatigue. The study will enroll about 26 participants to first check safety and then gather more information on potential benefits.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS (MF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Avigunda Gran via de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat
RECRUITINGBarcelona, 08908, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Azienda Ospedaliero Universitaria Careggi Firenze, Struttura Complessa di Ematologia
RECRUITINGFlorence, Florence, 50134, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Azienda Sanitario Universitaria Friuli Centrale
RECRUITINGUdine, 33100, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Universitario de Salamanca
RECRUITINGSalamanca, 37007, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
IRCCS Clinical Institute Humanitas
RECRUITINGRozzano, Milan, 20089, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Istituto di Ematolgia e Oncologia Medica
RECRUITINGBologna, 40138, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Vall d'Hebron University Hospital
RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.